Wafik El-Deiry argues mRNA vaccines should be tested for biodistribution and persistence to ensure potentially pathogenic antigens are appropriately evaluated, reflecting ongoing safety and regulatory scrutiny debates.
Point is if you’re developing an mRNA vaccine without control of biodistribution or persistence, manufacturers and regulators must ensure potentially pathogenic antigens
manufacturers and regulators must ensure potentially pathogenic antigens including those with potential activities to suppress host defenses against cancer are appropriately tested.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare